(Reuters) – Biogen and Ionis Pharmaceuticals said on Thursday they will terminate the development of their treatment for amyotrophic lateral sclerosis (ALS) based on results from an early-stage study.
(Reporting by Christy Santhosh; Editing by Sonia Cheema)
